<DOC>
	<DOCNO>NCT00076986</DOCNO>
	<brief_summary>The purpose PRECISE trial determine whether overall survival duration , safety , quality life improve patient treat IL13-PE38QQR compare patient treat GLIADEL® Wafer follow surgical tumor removal treatment first recurrence glioblastoma multiforme .</brief_summary>
	<brief_title>The PRECISE Trial : Study IL13-PE38QQR Compared GLIADEL Wafer Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>PRECISE Phase III clinical trial experimental drug IL13-PE38QQR ( Study Drug ) . IL13-PE38QQR tumor-targeting agent administer continuous infusion directly brain around cavity tumor remove . Through previous research , Study Drug show potential control recurrent malignant glioma , glioblastoma multiforme ( GBM ) , anaplastic astrocytoma , malignant mixed oligoastrocytoma . The Study Drug make combine human protein ( IL13 ) portion bacterial toxin protein , Pseudomonas Exotoxin ( PE ) . The IL13 portion bind receptor tumor like `` key lock , '' allow PE portion enter kill cell . Since tumor cell preferentially bind drug , normal ( healthy ) brain cell much less likely damage drug . The Study Drug deliver tube catheter place directly area surround resection cavity . These catheter surgically place 2-7 day tumor remove . A pump use slowly push drug solution catheter use convection-enhanced delivery ( CED ) period 4 day . The GLIADEL® Wafer anti-cancer drug approve U.S. Food Drug Administration ( FDA ) sell treatment recurrent newly diagnose GBM . Patients receive GLIADEL® wafer place time surgery remove tumor . Eligible patient enrol PRECISE trial randomly assign receive either IL13-PE38QQR GLIADEL® Wafer . Patients 2 3 chance receive IL13-PE38QQR 1 3 chance receive GLIADEL® Wafer .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Patients must ≥ 18 year old . Patients must clinical and/or radiographic evidence FIRST recurrence progression supratentorial GBM afer previous resection biopsy external beam radiation therapy . Patients must histopathologic documentation GBM initial diagnosis . Patients must previous cytoreductive surgery biopsy GBM . Patients must receive external beam radiotherapy ≥ 45 Gy tumor dose , complete ≥ 4 week prior study entry . Gross total resection ( i.e. , ≥ 95 % resection solid , contrastenhancing tumor component ) must plan . Tumor must solid contrastenhancing component ≥ 1.0 cm diameter . Baseline measurement must obtain ≤ 2 week prior study entry . Patients must adequate condition , indicate : 1 . Karnofsky Performance Score ≥ 70 , 2 . Adequate hematologic status : . Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; ii . Hemoglobin ≥ 10 gm/dL ; iii . Platelets ≥ 100,000/mm3 ; iv . PT aPTT ≤ 1.5 x institutional upper limit Patients must receive concurrent antitumor therapy must recover toxicity prior therapy . Minimum interval require : ≥ 6 week receive nitrosourea cytotoxic drug ≥ 4 week receive nonnitrosourea cytotoxic drug systemic investigational agent ≥ 2 week receive noncytotoxic antitumor drug ( include celecoxib drug , use antitumor therapy ) Patients must willing practice effective method birth control study . Female patient must pregnant breastfeeding . Patients legal representative must understand investigational nature study sign write informed consent form , approve Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) , prior performance studyspecific procedure Patients contrastenhancing tumor component cross midline , multifocal tumor amenable gross total resection , tumor dissemination ( subependymal leptomeningeal ) . Expected communication ventricle resection cavity repair order safely use GLIADEL® Wafer . Patients clinically significant increase intracranial pressure ( e.g. , impending herniation ) , uncontrolled seizure , requirement immediate palliative treatment . Patients receive type stereotactic radiosurgery brachytherapy , exception stereotactic radiosurgery boost part initial fractionate external beam radiation therapy . Patients receive : 1 ) prior treatment IL13PE38QQR , , 2 ) GLIADEL® Wafer , , 3 ) intracerebral investigational agent Patients demonstrate previous hypersensitivity BCNU component GLIADEL® Wafer . Patients unwilling unable follow protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>brain tumor</keyword>
	<keyword>recurrent malignant glioma</keyword>
	<keyword>brain neoplasm</keyword>
	<keyword>central nervous system</keyword>
	<keyword>surgery</keyword>
	<keyword>resection</keyword>
	<keyword>GLIADEL</keyword>
	<keyword>infusion</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>convection-enhanced delivery</keyword>
	<keyword>first recurrence</keyword>
	<keyword>recurrent GBM</keyword>
	<keyword>GBM</keyword>
	<keyword>supratentorial GBM</keyword>
</DOC>